The proposed Georgia Community Oncology Research Program (Community Site) represents the collaboration between two NCCCP community hospital-based cancer programs, Northside Hospital Cancer Institute in Atlanta, GA, and the Lewis Cancer &Research Pavilion at in Savannah, GA, with investigators from a statewide research network of community hospital-based and private practice oncologists through the Georgia Center for Oncology Research and Education (Georgia CORE). In 2013, the proposed Community Site consortium provided care to approximately 16,000 newly diagnosed patients with cancer in Georgia (33%) and has enrolled over 2,900 patients (includes 1,728 registry trial accruals) to NCI-sponsored trials since 2008. Through an integrated organizational and leadership structure, leading cancer researchers in the components and partner research sites are poised to build on a 25-year history of collaboration to further enhance the quality of cancer care through improved access and enrollment to NCI-sponsored trials to address the goals of the NCORP.
Three aims will guide the development, implementation, and evaluation of three primary research programs of the Community Site: Clinical, biospecimen, and cancer care delivery. In general, the aims will: 1) Establish and test an intervention model to increase the percentage of patients who have access to and enroll in cancer research in their own communities;2) Increase the number of biospecimens that are collected and used for cancer research;and 3) Overcome barriers to genetic risk screening, counseling and testing for high-risk women with a familial history of breast or ovarian cancer. The Community site aim achievement will improve the quality of care in Georgia through increased cancer research in local communities, identification of best practices for research accruals, and increased capacity and expertise for cancer research statewide.
The proposed research addresses a significant obstacle in the US public health. Cancer has been defined as more than 100 different diseases making cancer care delivery in the community setting a robust challenge that can only be adequately addressed with expanded community clinical research.
|Tarhini, Ahmad A; Lee, Sandra J; Li, Xiaoxue et al. (2018) E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-?2b in Advanced Melanoma. Clin Cancer Res :|
|West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92|